- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Renal Cell Carcinoma | Clinical
Updated Findings Support Pembrolizumab/Lenvatinib as a Standout Option for Frontline RCC Treatment
July 24, 2021
In an interview, Robert J. Motzer, MD, explained how further results of the CLEAR trial, including health-related QOL data, suggest the benefit of pembrolizumab and lenvatinib in patients with advanced RCC.
Overall Survival Results of I/O Combinations Differ Across Risk Groups of Metastatic RCC
July 22, 2021
The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.
ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma
July 08, 2021
ARO-HIF2, an investigational tumor-targeting medicine utilizing the Targeted RNAi molecule platform from Arrowhead Pharmaceuticals, Inc., may be a safe and effective treatment for patients with clear cell renal cell carcinoma.
Choueiri Discusses RCC Immunotherapy Updates at ASCO 2021
July 08, 2021
In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed the results of the KEYNOTE-564 trial as well as the potential effects of these findings.
Follow-Up Shows Continued Efficacy in RCC With Pembrolizumab/Axitinib
July 07, 2021
Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.
The Future of Therapy for Advanced RCC
June 29, 2021
Robert J. Motzer, MD, shares his insights on the future of treatment for advanced renal cell carcinoma.
Updates on CLEAR from ASCO 2021
June 29, 2021
Dr Motzer discusses data from the CLEAR trial that were presented at ASCO 2021.
Impact of the CLEAR Trial on Clinical Practice
June 29, 2021
An expert explains the impact of the CLEAR trial on clinical practice and reviews NCCN guidelines for the management of advanced renal cell carcinoma.
Key Efficacy and Safety Findings from the CLEAR Trial
June 29, 2021
Dr Robert J. Motzer introduces data from the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus for the treatment of advanced renal cell carcinoma.
Current Therapies for Advanced RCC: Options and Challenges
June 29, 2021
Robert J. Motzer, MD, gives a background on the current first-line therapy options for advanced renal cell carcinoma, including challenges and unmet needs.